Fig. 4

Transcriptomics, survival, tamoxifen therapy response and endocrine resistance mutations. A Hierarchical clustering of ER+ primary BCs (pBCs) based on 2,867 genes differentially expressed (regression model p-value < 0.05) between TP53 mutant and wild-type ER+ pBCs. CHEK2* pBCs in purple and TP53 mutant ER+ pBCs in orange. B Disease-free survival and C overall response to first-line tamoxifen among CHEK2 c.1100delC mutation carriers, BC patients with a somatic TP53 mutation and BC patients wild-type for both alleles. D Mutation frequency of the endocrine resistance gene IGF1R among CHEK2 and ER+ metastatic BCs